Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy

Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy

Aim: to evaluate the pharmacoeconomic efficacy of the application of the atesolizumab (PD-L1 inhibitor) preparation compared with other control point inhibitors (PD-1 inhibitors) in patients with advanced non-small cell lung cancer (NSCLC) after chemothe rapy.Materials and methods. Study design incl...

Full description

Bibliographic Details
Main Authors: S. K. Zyryanov, I. N. Diyakov
Format: Article
Language:Russian
Published: IRBIS LLC 2020-04-01
Series:Фармакоэкономика
Subjects:
common non-small cell lung cancer
second line of therapy
third line of therapy
control point inhibitors
pd-1/pd-l1 inhibitors
atesolizumab
pembrolizumab
nivolumab
cost minimization
budget impact
Online Access:https://www.pharmacoeconomics.ru/jour/article/view/338

Internet

https://www.pharmacoeconomics.ru/jour/article/view/338

Similar Items